A Phase I/II Study of IMMU-132 (hRS7-SN38 Antibody Drug Conjugate) in Patients With Epithelial Cancers

Trial Profile

A Phase I/II Study of IMMU-132 (hRS7-SN38 Antibody Drug Conjugate) in Patients With Epithelial Cancers

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 09 Dec 2017

At a glance

  • Drugs Sacituzumab govitecan (Primary)
  • Indications Adenocarcinoma; Advanced breast cancer; Bladder cancer; Cervical cancer; Colorectal cancer; Endometrial cancer; Gastric cancer; Glioblastoma; Head and neck cancer; Liver cancer; Non-small cell lung cancer; Oesophageal cancer; Ovarian cancer; Pancreatic cancer; Prostate cancer; Renal cell carcinoma; Small cell lung cancer; Solid tumours; Squamous cell cancer; Thyroid cancer; Urogenital cancer
  • Focus Adverse reactions; Proof of concept; Therapeutic Use
  • Sponsors Immunomedics
  • Most Recent Events

    • 09 Dec 2017 Results (n=110) presented at the 40th Annual San Antonio Breast Cancer Symposium
    • 06 Dec 2017 Results in mTNBC patients (n=110) presented at the 2017 San Antonio Breast Cancer Symposium, according to an Immunomedics media release.
    • 13 Nov 2017 According to an Immunomedics media release, BLA submission planned in the first quarter of 2018 to the FDA for accelerated approval as third-line treatment for mTNBC.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top